Author Index

AARLI, J.A., STEANSSON, K., MARTON, L.S.G. & WOLLMANN, R.L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin, 284
ABAITUA, I. *see* TEN, R.M.
ABUAF, N. *see* DIGHIERO, G.
AGLEICHMANN, E. PALS, S.T. *see* ROZENDAAL, L.
AHO, K. *see* KOURI, T.
AKASU, F. *see* MATSUBAYASHI, S.
ALEXANDER, G.J.M. *see* DE LA MATA, M.
ALEXANDER, G.J.M. *see* SHERON, N.
ALVAREZ-CERMEÑO, J.C. *see* BRIEVA, J.A.
ANDERSSON, G. *see* KARTTUNEN, R.
ARAI, K. *see* ARITA, C.
ARITA, C., HOTOKEBUCHI, T., MIYAHARA, H., ARAI, K., SUGIOKA, Y. & KAIBARA, N. Inhibition by FK506 of established lesions of collagen-induced arthritis in rats, 456
ARMITAGE, J. *see* WU, D.P.
ARVIEUX, J. *see* ROUSSEL, B.
ASSEMI, C. *see* WAGNER, F.

BALBOA, M.A. *see* IZQUIERDO, M.
BECK, J.M., SUZARA, V.V. & SHELLITO, J. Chronic oral administration of dexamethasone to rats increases cytotoxicity, but not interleukin-1 elaboration, by alveolar macrophages, 157
BENCZUR, M. *see* POCSIK, E.
BERDEN, J.H.M. *see* TERMAAT, R.M.
BERG, K. *see* ROSS, C.
BERG, P.A. *see* KLEIN, R.
BEVERLEY, P.C.L. *see* SMITH-RAVIN, J.
BJELLE, A. *see* NILSSON, B.
BJERKE, K. & BRANDZAEG, P. Terminally differentiated human B cells. J chain expression of IgA and IgG subclass producing immunocytes in the distal ileum compared with mesenteric and peripheral lymph nodes, 411
BOCTOR, F.N. & PETER, J.B. IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and non-specific IgG4, 574
BORDIER, C. *see* CHIRON, M.
BRANDELY, M. *see* CHIRON, M.
BRANDELY, M. *see* FARACE, F.
BRANDZAEG, P. *see* BJERKE, K.
BRCIC, M. *see* JUNGI, T.W.
BREEDVELD, F.C. *see* MILTENBURG, A.M.M.
BRESSON, J.L. *see* BRESSON-HADNI, S.
BRESSON-HADNI, S. *see* LIANCE, M.
BRESSON-HADNI, S., LIANCE, M., MEYER, J.P., HOUIN, R., BRESSON, J.L. & VUITTON, D.A. Cellular immunity in experimental *Echinococcus multilocularis* infection. II. Sequential and comparative phenotypic study of the periparasitic mononuclear cells in resistant, 378
BRIEVA, J.A., VOLLAR, L.M., LEORO, G., ALVAREZ-CERMEÑO, J.C. ROLD N.E. & GONZALEZ-PORQUÉ, P. Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma, 390
BRIGGS, J.D. *see* SANDILANDS, G.P.
BRIJS, L. *see* VANHAM, G.
BRINKMAN, K. *see* TERMAAT, R.M.
BRITTON, S. *see* CONVERSE, P.J.
BROOKS, B., CHAPMAN, K., LAWRY, J., MEAGER, A. & REES, R.C. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-α1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production, 583
BROWN, A.E., WEBSTER, H.K., TEJA-ISAVADHARAM, P. & KEERATITHAKUL, D. Macrophage activation in falciparum malaria as measured by neopterin and interferon-gamma, 97
BROWNLEE, A. *see* LAI, K.N.

CAMERON, J.S. *see* FRAMPTON, G.
CAPLAN, B.U. *see* KLEIN, A.
CAPRON, A. *see* LASSALLE, P.
CAPRON, M. *see* LASSALLE, P.
CARAYON, P. *see* CHIRON, M.
CARBONETTO, C.H., MALCHIODI, E.L., CHIARAMONTE, M., DURANTE DE ISOLA, E., FOSSATI, C.A. & MARGNI, R.A. Isolation of *Trypanosoma cruzi* antigen by affinity chromatography with a monoclonal antibody. Preliminary evaluation of its possible applications in serological tests, 93
CARLSTEN, H. *see* TROLLMO, C.
CARSON, D. *see* KOURI, T.
CASTAGNOLI, C., STELLA, M., MAGLIACANI, G., TEICH ALASIA, S. & RICHIARDI, P. Anomalous expression of HLA class II molecules on keratinocytes and fibroblasts in hypertrophic scars subsequent to thermal injury, 350
CAVALLO, T. & GRANHOLM, N.A. Lipopolysaccharide from Gram-negative bacteria enhances polyclonal B cell activation and exacerbates nephrits in MRL/*lpr* mice, 515
CAVALLO, T. *see* GRANHOLM, N.A.
CAVIGIOLI, E. *see* ROUSSEL, B.
CEUPPENS, J.L. *see* VANHAM, G.
CHAN, A.W.-L. *see* KLEIN, A.
CHAPEL, H.M. *see* EGNER, W.
CHAPMAN, K. *see* BROOKS, B.
CHEN, K. *see* YOO, Y.K.
CHIARAMONTE, M. *see* CARBONETTO, C.H.
CHIRON, M., JAFFERZOU, J.P., CARAYON, P., BORDIER, C., ROUBINET, F., XAVIER, C., BRANDELY, M. & LAURENT, G. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity, 214
CHUANG, J.C., YU, C.L. & WANG, S.R. Modulation of lymphocyte proliferation by enzymes that degrade amino acids, 469
CICLITIRA, P.J. *see* STURGESS, R.P.
CLASSEN, M. *see* WAGNER, F.
COLEBUNDERS, R. *see* VANHEM, G.
CONVERSE, P.J., FEHNIGER, T.E., EHRNST, A., STRANNEGARD, O. & BRITTON, S. Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV^-, CMV^+ individuals, 559
CREMER, M.A., TOWNES, A.S. & KANG, A.H. Adjuvant-induced arthritis in rats. Evidence that autoimmunity to homologous collagens types I, II, IX, and XI is not involved in the pathogenesis of arthritis, 307
CROCKER, J.E. *see* SANDILANDS, G.P.
CROWLEY, J. *see* KOURI, T.
CZUPRYNSKI, C.J. *see* HAAK-FRENDSCHO, M.

DAHA, M.R. *see* MILTENBURG, A.M.M.
DANG, H. *see* MILLER, A.L.
DANIELS, H.M. *see* DE LA MATA, M.
DARROW, R. *see* ZWILLING, B.S.
DAVIES, A.J.S. *see* WAWRZYNCZAK, E.J.
DAVIES, D.J. *see* SAVIGE, J.A.
DAVISON, A.N. *see* OWEN, S.J.
DE CAROLIS, C. *see* PERRICONE, R.
DE KUIPER, P. *see* MILTENBURG, A.M.M.
DE LA MATA, M., MEAGER, A., ROLANDO, N., DANIELS, H.M., NOURI-ARIA, K.T., GOKA, A.K.J., EDDLESTON, A.L.W.F., ALEXANDER, G.J.M. & WILLIAMS, R. Tumour necrosis factor production in fulminant hepatic failure: relations to aetiology and superimposed microbial infection, 479
DE SANCTIS, G. *see* PERRICONE, R.
DE VRIES, J.E. *see* PASTORELLI, G.
DECLARLE, D. *see* DEVERY, J.M.

DEVERY, J.M., GECZY, C.L., DECLARLE, D., SKERRITT, J.H. & KRILLIS, S.A. Macrophage procoagulant activity as an assay of cellular hypersensitivity to gluten peptides in coeliac disease, 333
DIAZ-SANCHES, D. *see* KEMENY, D.M.
DIGHIERO, G., LYMBERI, P., MONOT, C. & ABUAF, N. Sera with levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins, 52
DIVINE, M. *see* OUDRHIRI, N.
DORVAL, T. *see* FARACE, F.
DOUGLAS, J.T., HIRSCH, D.S., FAJARDO, T.T., GUIDO, L.S. & KLASTER, P.R. Serological monitoring of previously treated epromatous patients during a course of multiple immunotherapy treatments with heat-killed *Mycobacterium leprae* and BCG, 567
DREXHAGE, H.A. *see* VOORBY, H.A.M.
DUNNETTE, S.L. *see* TEN, R.M.
DURANTE DE ISOLA, E. *see* CARBONETTO, C.H.

EBERT, E.C. Intra-epithelial lymphocytes: interferon-gamma production and suppressor/cytotoxic activities, 81
EDDLESTON, A.L.W.F. *see* DE LA MATA, M.
EDWIN, S.S. *see* PARK, M.I.
EGNER, W. & CHAPEL, H.M. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides, 244
EGUCHI, K. *see* MIGITA, K.
EHRNST, A. *see* CONVERSE, P.J.
EMURA, M., NAGAI, S., TAKEUCHI, M., KITAICHI, M. & IZUMI, T. *In vitro* production of B cell growth factor and B cell differentiation factor by peripheral blood mononuclear cells and bronchoalveolar lavage T lymphocytes from patients with idiopathic pulmonary, 133

FAJARDO, T.T. *see* DOUGLAS, J.T.
FARACE, F., MATHIOT, C., BRANDELY, M., TURSZ, T., DORVAL, T., POUILLART, P., TREIBEL, F., HERCEND, T. & FRIDMAN, W.H. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma, 194
FARCET, J.P. *see* OUDRHIRI, N.
FEHNIGER, T.E. *see* CONVERSE, P.J.
FERNANDEZ-RANADA, J.M. *see* IZQUIERDO, M.
FIGUERA, A. *see* IZQUIERDO, M.
FLEXMAN, J.P., MANNING, L.S. & ROBINSON, B.W.S. *In vivo* boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes, 151
FONTANA, L. *see* PERRICONE, R.
FORTUNE, F., WALKER, J. & LEHNER, T. The expression of k T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behçet's syndrome, 326
FOSSATI, C.A. *see* CARBONETTO, C.H.
FRAMPTON, G., JAYNE, D.R.W., PERRY, G.J., LOCKWOOD, C.M. & CAMERON, J.S. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis, 227
FREEMAN, M. *see* WEETMAN, A.P.
FRIDMAN, W.H. *see* FARACE, F.
FROLAND, S.S. *see* MULLER, F.
FUKUDA, T. *see* MIGITA, K.
FUKUI, H. *see* MIHARA, M.
FUKUMA, N., MCLACHLAN, S.M., RAPOPORT, B., GOODACRE, J., MIDDLETON, S.L., PHILLIPS, D.I.W., PEGG, C.A.S. & REES SMITH, B. Thyroid autoantigens and human T cell responses, 275
FUKUMOTO, T. *see* TAKAI, K.
FULLER, L. *see* HAYNES, M.K.

GALANOPOULOU, V. *see* KATZIKIS, P.D.
GALAZKA, A. *see* OUDRHIRI, N.
GALLAGHER, A. *see* MAHIDA, Y.R.
GALLICCHIO, M. *see* SAVIGE, J.A.
GASTON, J.S.H. Editorial Review: How does HLA-B27 confer susceptibility to inflammatory arthritis?, 1
GAULARD, P.H. *see* OUDRHIRI, N.
GAVALER, J.B. *see* YOO, Y.K.
GECZY, C.L. *see* DEVERY, J.M.
GEORGIOU, T. *see* SAVIGE, J.A.
GERRARD, J.M. *see* ROUSSEL, E.
GIGASE, P. *see* VANHAM, G.
GILKESON, G.S. *see* WU, D.P.
GLEICH, G.J. *see* TEN, R.M.
GOKA, A.K.J. *see* DE LA MATA, M.
GONZALEZ-PORQUÉ, P. *see* BRIEVA, J.A.
GOODACRE, J. *see* FUKUMA, N.
GOSSET, P. *see* LASSALLE, P.
GOURDIN, M.F. *see* OUDRHIRI, N.
GRAHAM, C.A. *see* MCMILLAN, S.A.
GRANHOLM, N.A. & CAVALLO, T. Prolonged circulation of immune complexes due to various altered immune functions contributes to nephritis in MRL/*lpr* mice, 300
GRANHOLM, N.A. *see* CAVALLO, T.
GREENBERG, A.H. *see* ROUSSEL, E.
GRUART, V. *see* LASSALLE, P.
GUIDO, L.S. *see* DOUGLAS, J.T.
GYODI, E. *see* POCSIK, E.

HAAK-FRENDSCHO, M., WYNN, T.A., CZUPRYNSKI, C.J. & PAULNOCK, D. Transforming growth factor-α1 inhibits activation of macrophage cell line RAW 264.7 for cell killing, 404
HÅBERG, H. *see* LÖVGREN, K.
HADDEN, D.R. *see* MCMILLAN, S.A.
HAMACHI, M. *see* TOUBERT, A.
HAMADA, S. *see* OGAWA, T.
HANSEN, M.B. *see* ROSS, C.
HARLEY, C. *see* WING, M.G.
HART, P.J. *see* MCMILLAN, S.A.
HART, R. *see* WAGNER, F.
HASKARD, D.O. *see* STURGESS, R.P.
HAWKEY, C.J. *see* MAHIDA, Y.R.
HAYGLASS, K.T. & STEFURA, W. Isotype-selective abrogation of established IgE responses, 429
HAYNES, M.K., MILLER, J. & FULLER, L. $Cd8^+/DR^+$ gamma cells inhibit autologous mixed lymphocyte reaction, 174
HELIÖVAARA, M. *see* KOURI, T.
HELTAI, S. *see* ZOCCHI, M.R.
HERCEND, T. *see* FARACE, F.
HIRSCH, D.S. *see* DOUGLAS, J.T.
HOFFMAN, J. *see* SHERON, N.
HOLLAND, G.P., HOLLAND, N. & STEWARD, M.W. Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation, 221
HOLLAND, N. *see* HOLLAND, G.P.
HORST, G. *see* TER BORG, B.J.
HOTOKEBUCHI, T. *see* ARITA, C.
HOUIN, R. *see* BRESSON-HADNI, S.
HOUIN, R. *see* LIANCE, M.
HOUSSAINT, E., POGU, S., OURAY, M. & SAI, P. Monoclonal autoantibodies from insulin-dependent diabetic patients: autoantibodies against β-cell surface or cytoplasmic antigens, 44
HUNG, C.-H. *see* STURGESS, R.P.
HUSBY, G. *see* TSUCHIYA, N.
HUYGEN, K., PALFLIET, K., JURION, F., LENOIR, C. & VAN VOOREN, J.-P. Antibody repertoire against culture filtrates in wild house mice infected with *Mycobacterium bovis* BCG, 369

IMAI, K. *see* TAKAHASHI, T.
IMAOKA, K., KANA, Y., YOSHIKAWA, Y. & YAMANOUCHI, K. Temporary breakdown of immunological tolerance to dsDNA and nucleohistone antigens in rabbits infected with rinderpest virus, 522
INVERARDI, L. *see* ZOCCHI, M.R.
IRIONDO, A. *see* IZQUIERDO, M.
ISAACSON, P.G. *see* SMITH-RAVIN, J.
ISOMÄKI, H. *see* KOURI, T.
ITO, K. *see* MIGITA, K.
IZQUIERDO, M., BALBOA, M.A., FERNANDEZ-RANADA, J.M., FIGUERA, A., TORRES, A., IRIONDO, A. & LOPEZ-BOTET, M. Relation between the increase of circulating $CD3^+CD57^+$ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation, 145
IZUMI, T. *see* EMURA, M.

JACOB, M.C. *see* ROUSSEL, B.
JAFFERZOU, J.P. *see* CHIRON, M.
JAYNE, D.R.W. *see* FRAMPTON, G.
JAYNE, D.R.W *see* LAI, K.N.
JEUCKEN, P.H.M. *see* VOORBY, H.A.M.
JOJIMA, K. *see* TAKAI, K.
JUNGI, T.W., BRCIC, M., KUHNERT, P., SPYCHER, M.O., LI, F. & NYDEGGER, U.E. Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes, 163
JUNOR, B.J.R. *see* SANDILANDS, G.P.
JURION, F. *see* HUYGEN, K.
JUUTINEN, K. *see* KARTTUNEN, R.

KADOTA, S. *see* TAGUCHI, H.
KAIBARA, N. *see* ARITA, C.
KALLENBERG, C.G.M. *see* TER BORG, B.J.
KANA, Y. *see* IMAOKA, K.
KANAI, M. *see* KOHDA, H.
KANAZAWA, K. *see* TAGUCHI, H.
KANG, A.H. *see* CREMER, M.A.
KANOH, M. *see* TAGUCHI, H.
KARTTUNEN, R., ANDERSSON, G., POIKONEN, K., KOSUNEN, T.U., KARTTUNEN, T., JUUTINEN, K. & NIEMLA, S. *Heliobacter pylori* induces lymphocyte activation in peripheral blood cultures, 485
KARTTUNEN, T. *see* KARTTUNEN, R.
KASUGA, Y. *see* MATSUBAYASHI, S.
KATZ, A. *see* OUDRHIRI, N.
KATZIKIS, P.D., YOUINOU, P.Y., GALANOPOULOU, V., PAPADOPOULOS, N.M., TZIOUFAS, A.G. & MOUTSOPOULOS, H.M. Monoclonal process in primary Sjörgen's syndrome and cross-reactive idiotype associated with rheumatoid factor, 509
KAWAKAMI, A. *see* MIGITA, K.
KEERATITHAKUL, D. *see* BROWN, A.E.
KEMENY, D.M. & DIAZ-SANCHES, D. Editorial Review: Can persistent IgE responses be suppressed?, 423
KEPHART, G.M. *see* TEN, R.M.
KESTENS, L. *see* VANHAM, G.
KEYSTONE, E. & MATSUBAYASHI, S.
KIKUCHI, K. *see* KOHDA, H.
KILBOURNE, E.M. *see* TEN, R.M.
KITAICHI, M. *see* EMURA, M.
KIYONO, H. *see* OGAWA, T.
KLASTER, P.R. *see* DOUGLAS, J.T.
KLEIN, A., CHAN, A.W.-L., CAPLAN, B.U. & MALKIN, A. NADP+ reduction by human lymphocytes, 170
KLEIN, R. & BERG, P.A. Anti-mitochondrial antibodies (anti-M7) in heart diseases recognize epitopes on bacterial and mammalian sacrosine dehydrogenase, 289
KOBAYASHI, Y. *see* SAYAMA, K.
KOHDA, H., SEKIYA, C., KANAI, M., YOSHIDA, Y., UEDE, T., KIKUCHI, K. & NAMIKI, M. Flow cytometric and functional analysis of mononuclear cells infiltrating the liver in experimental autoimmune hepatitis, 473
KOISHIHARA, Y. *see* MIHARA, M.
KOSUNEN, T.U. *see* KARTTUNEN, R.
KOURI, T., CROWLEY, J., AHO, K., PALOSUO, T., ISOMÄKI, H., VON ESSEN, R., HELIÖVAARA, M., CARSON, D. & VAUGHAN, J.H. Occurrence of two germline-related rheumatoid factor idiotypes in rheumatoid arthritis and in non-rheumatoid positive individuals, 250
KRILLIS, S.A. *see* DEVERY, J.M.
KUHNERT, P. *see* JUNGI, T.W.
KURATA, A. *see* MIGITA, K.
KURLAK, L. *see* MAHIDA, Y.R.
KUSNIERZ, J.P. *see* LASSALLE, P.
KUSUMOTO, Y. *see* OGAWA, T.

LACHMANN, P.J. *see* MONTGOMERY, A.M.P.
LACHMANN, P.J. *see* WING, M.G.
LAGRUE, C. *see* LASSALLE, P.
LAI, K.N., JAYNE, D.R.W., BROWNLEE, A. & LOCKWOOD, C.M. The specificity of anti-neutrophil cytoplasm autoantibodies in systemic vasculitides, 233
LASSALLE, P., GOSSET, P., GRUART, V., PRIN, L., CAPRON, M., LAGRUE, G., KUSNIERZ, J.P., TONNEL, A.B. & CAPRON, A. Presence of antibodies against endothelial cells in the sera of patients with episodic angioedema and hypereosinophilia, 38
LAU, J.N. *see* SHERON, N.
LAUFMAN, H. *see* ZWILLING, B.S.
LAURENT, G. *see* CHIRON, M.
LAWRY, J. *see* BROOKS, B.
LEHNER, T. *see* FORTUNE, F.
LENOIR, C. *see* HUYGEN, K.
LEORO, G. *see* BRIEVA, J.A.
LERSCH, C. *see* WAGNER, F.
LI, F. *see* JUNGI, T.W.
LIANCE, M. *see* BRESSON-HADNI, S.
LIANCE, M., BRESSON-HADNI, S., MEYER, J.-P., HOUIN, R. & VUITTON, D.A. Cellular immunity in experimental *Echinococcus multilocularis* infection. I. Sequential and comparative study of specific *in vivo* delayed-type hypersensitivity against *E. multilocularis* antigens in resistant and sensitive mice, 373
LILLIEHORN, P. *see* NILSSON, R.
LIMBURG, P.C. *see* TER BORG, B.J.
LINDGREN, L. *see* NILSSON, R.
LOCKWOOD, C.M. *see* FRAMPTON, G.
LOCKWOOD, C.M. *see* LAI, K.N.
LOPEZ-BOTET, M. *see* IZQUIERDO, M.
LORIMIER, P. *see* ROUSSEL, B.
LÖVGREN, K., HÄBERG, H. & MOREIN, B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration, 435
LYMBERI, P. *see* DIGHIERO, G.

M'BEMBA, E. *see* OUDRHIRI, N.
MACARTNEY, J.C. *see* STURGESS, R.P.
MACLOED, A.M. *see* WOO, J.
MACSWEEN, R.N.M. *see* SANDILANDS, G.P.
MAEZAWA, A. *see* OKUBO, Y.
MAGLIACANI, G. *see* CASTAGNOLI, C.
MAHIDA, Y.R., GALLAGHER, A., KURLAK, L. & HAWKEY, C.J. Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease, 75
MAKGOBA, M.W. *see* STURGESS, R.P.
MALCHIODI, E.L. *see* CARBONETTO, C.H.
MALKIN, A. *see* KLEIN, A.
MANNING, L.S. *see* FLEXMAN, J.P.
MARGNI, R.A. *see* CARBONETTO, C.H.
MARSDEN, H. *see* SANDILANDS, G.P.
MARTON, L.S.G. *see* AARLI, J.A.
MATHIOT, C. *see* FARACE, F.
MATSUBAYASHI, S., AKASU, F., KASUGA, Y., SNOW, K., KEYSTONE, E. & VOLPE, R. *In vitro* production of interferon-gamma by peripheral blood from patients with Graves' disease, Hashimoto's thyroiditis and rheumatoid arthritis, 63
MATSUNAGA, M. *see* MIGITA, K.
MCGHEE, J.R. *see* OGAWA, T.
MCLACHLAN, S.M. *see* FUKUMA, N.
MCMILLAN, M.A. *see* SANDILANDS, G.P.
MCMILLAN, S.A., GRAHAM, C.A., HART, P.J., HADDEN, D.R. & MCNEILL, T.A. A T cell receptor beta chain polymorphism is associated with patients developing insulin-dependent diabetes after the age of 20 years, 538
MCNEILL, T.A. *see* MCMILLAN, S.A.
MCPEEK, M. *see* ZWILLING, B.S.
MEAGER, A. *see* BROOKS, B.
MEAGER, A. *see* DE LA MATA, M.
MELIEF, C.J.M. *see* ROZENDAAL, L.
MENDELOVIC, S., SEGAL, R., SHOENFIELD, Y. & MOZES, E. Anti-DNA idiotype- and anti-idiotype-specific T cell response in patients with systemic lupus erythematosus and their first-degree relatives, 504
MEYER, J.-P. *see* LIANCE, M.
MEYER, J.P. *see* BRESSON-HADNI, S.
MICOUIN, C. *see* ROUSSEL, B.
MIDDLETON, S.L. *see* FUKUMA, N.
MIGITA, K., EGUCHI, K., OTSUBO, T., KAWAKAMI, A., NAKAO, H., UEKI, Y., SHIMOMURA, C., KURATA, A., FUKUDA, T., MATSUNAGA, M., ITO, K. & NAGATAKI, N. Cytokine regulation of HLA on thyroid epithelial cells, 548

MIHALIK, R. *see* POCSIK, E.
MIHARA, M., FUKUI, H., KOISHIHARA, Y., SAITO, M. & OHSUGI, Y. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6, 533
MIKI, Y. *see* SAYAMA, K.
MILLER, A.L., DANG, H. & TALAL, N. Accelerated expression of anti-Sm and Y2 idiotype differ in dependence on T cell subsets in MRL/$^+$ mice, 27
MILLER, J. *see* HAYNES, M.K.
MILTENBURG, A.M.M., VAN LAAR, J.M., DE KUIPER, P., DAHA, M.R. & BREEDVELD, F.C. Cytolytic activity in T cell clones derived from human synovial rheumatoid membrane: inhibition by synovial fluid, 499
MIYAHARA, H. *see* ARITA, C.
MONOT, C. *see* DIGHIERO, G.
MONTGOMERY, A.M.P. *see* WING, M.G.
MONTGOMERY, A.M.P., WING, M.G. & LACHMANN, P.J. A novel strategy for targeting CD4$^+$ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates, 200
MOREIN, B. *see* LOVGREN, K.
MORETTI, E. *see* PERRICONE, R.
MORGAN, B.P. *see* WEETMAN, A.P.
MOUTSOPOULOS, H.M. *see* KATZIKIS, P.D.
MOZES, E. *see* MENDELOVIC, S.
MULLER, F., ROLLAG, H. & FROLAND, S.S. Reduced oxidative burst responses in monocytes and monocyte-derived macrophages from HIV-infected subjects, 10

NAGAI, S. *see* EMURA, M.
NAGASAWA, K. *see* TSUKAMOTO, H.
NAGATAKI, N. *see* MIGITA, K.
NAKAO, H. *see* MIGITA, K.
NAMIKI, M. *see* KOHDA, H.
NARUSE, T. *see* OKUBO, Y.
NIEMLA, S. *see* KARTTUNEN, R.
NIHO, Y. *see* TSUKAMOTO, H.
NIJSTEN, M.W.N. *see* POS, O.
NILSSON EKDAHL, K. *see* NILSSON, B.
NILSSON, B., NILSSON EKDAHL, K., SVARVARE, M., BJELLE, A. & NILSSON, U.R. Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function, 262
NILSSON, R., LINDGREN, L. & LILLIEHORN, P. Extracorporeal immunoadsorption therapy on rats. *In vivo* depletion of specific antibodies, 440
NILSSON, U.R. *see* NILSSON, B.
NOSSENT, J.C. *see* TERMAAT, R.M.
NOURI-ARIA, K.T. *see* DE LA MATA, M.
NYDEGGER, U.E. *see* JUNGI, T.W.

OGAWA, T., KUSUMOTO, Y., HAMADA, S., MCGHEE, J.R. & KIYONO, H. Bacteroides gingivalis-specific serum IgG and IgA subclass antibodies in periodontal diseases, 318
OHSUGI, Y. *see* MIHARA, M.
OKADA, H. *see* SAYAMA, K.
OKADA, N. *see* SAYAMA, K.
OKUBO, Y., TSUKADA, Y., MAEZAWA, A., ONO, K., YANO, S. & NARUSE, T. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of masugi nephritis, 450
ONO, K. *see* OKUBO, Y.
OTSUBO, T. *see* MIGITA, K.
OUDRHIRI, N., FARCET, J.P., GOURDIN, M.F., M'BEMBA, E., GAULARD, P.H., KATZ, A., DIVINE, M., GALAZKA, A. & REYES, F. CD3–T cell receptor modulation is selectively induced in CD8 but not CD4 lymphocytes cultured in agar, 396
OURAY, M. *see* HOUSSAINT, E.
OWEN, S.J., WATSON, C.M. & DAVISON, A.N. Degradation of human myelin *in vitro* by leucocytes from patients with multiple sclerosis, 86
OWSIANKA, A.M. *see* SANDILANDS, G.P.

PALFLIET, K. *see* HUYGEN, K.
PALOCZI, K. *see* POCSIK, E.
PALOSUO, T. *see* KOURI, T.
PAPADOPOULOS, N.M. *see* KATZIKIS, P.D.
PARK, M.I., EDWIN, S.S., SCOTT, J.R. & WARE BRANCH, D. Interpretation of blocking activity in maternal serum depends on the equation used for calculation of mixed lymphocyte culture results, 363
PARK, M.S. *see* TOUBERT, A.
PASTORELLI, G., RONCAROLO, M.G., PERONNE, C., TOVO, P.A. & DE VRIES, J.E. The capacity of interleukin-4 to induce *in vitro* IgE synthesis by B cells of patients with common variable immunodeficiency, 120
PASTORELLI, G., ROUSSET, F., PENE, J., PERONNE, C., RONCAROLO, M.G., TOVO, P.A. & DE VRIES, J.E. Cord blood B cells are mature in their capacity to switch to IgE-producing cells in response to interleukin-4 *in vitro*, 114
PAULNOCK, D. *see* HAAK-FRENDSCHO, M.
PEARL, D. *see* ZWILLING, B.S.
PEGG, C.A.S. *see* FUKUMA, N.
PENE, J. *see* PASTORELLI, G.
PERONNE, C. *see* PASTORELLI, G.
PERRICONE, R., DE CAROLIS, C., MORETTI, E., DE SANCTIS, G. & FONTANA, L. Complement, complement activation and anaphylatoxins in human ovarian follicular fluid, 359
PERRY, G.J. *see* FRAMPTON, G.
PETER, J.B. *see* BOCTOR, F.N.
PETRANYI, G.G. *see* POCSIK, E.
PHILLIPS, D.I.W. *see* FUKUMA, N.
PISETSKY, D.S. *see* WU, D.P.
POCSIK, E., MIHALIK, R., GYODI, E., RETI, M., PALOCZI, K., PETRANYI, G.G. & BENCZUR, M. Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product, 102
POGGI, A. *see* ZOCCHI, M.R.
POGU, S. *see* HOUSSAINT, E.

POIKONEN, K. *see* KARTTUNEN, R.
POS, O., VAN DER STELT, M.E., WOLBINK, G.-J., NIJSTEN, M.W.N., VAN DER TEMPEL, G.L. & VAN DIJK, W. Changes in the serum concentration and the glycosylation of human α1-acid glycoprotein and α1-protease inhibitor in severely burned persons: relation to interleukin-6 levels, 579
POSADA, M. *see* TEN, R.M.
POUILLART, P. *see* FARACE, F.
PRIN, L. *see* LASSALLE, P.
PROPPER, D.J. *see* WOO, J.

RAFFOUX, C. *see* TOUBERT, A.
RAPOPORT, B. *see* FUKUMA, N.
REES SMITH, B. *see* FUKUMA, N.
REES, R.C. *see* BROOKS, B.
REICH, C.F. *see* WU, D.P.
RETI, M. *see* POCSIK, E.
REYES, F. *see* OUDRHIRI, N.
RICHIARDI, P. *see* CASTAGNOLI, C.
ROBINSON, B.W.S. *see* FLEXMAN, J.P.
ROLANDO, N. *see* DE LA MATA, M.
ROLD, N.E. *see* BRIEVA, J.A.
ROLLAG, H. *see* MULLER, F.
RONCAROLO, M.G. *see* PASTORELLI, G.
ROSS, C., HANSEN, M.B., SCHYBERG, T. & BERG, K. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors, 57
ROUBINET F. *see* CHIRON, M.
ROUSSEL, B., ARVIEUX, J., JACOB, M.C., LORIMIER, P., CAVIGIOLI, E. & MICOUIN, C. A human monoclonal IgM with autoantibody activities against heparan sulphate and the mitotic spindle, 294
ROUSSEL, E., GERRARD, J.M. & GREENBERG, A.H. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3$^+$ CD16$^-$CD56$^-$ large granular lymphocyte LAK cells, 416
ROUSSET, F. *see* PASTORELLI, G.
ROZENDAAL, L., AGLEICHMANN, E. PALS, S.T. & MELIEF, C.J.M. Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-*versus*-host disease, 527

SABBADINI, M.G. *see* ZOCCHI, M.R.
SAI, P. *see* HOUSSAINT, E.
SAITO, M. *see* MIHARA, M.
SAKATOKU, J. *see* TAKAI, K.
SANDILANDS, G.P., CROCKER, J.E., MCMILLAN, M.A., OWSIANKA, A.M., MARSDEN, H., JUNOR, B.J.R., BRIGGS, J.D. & MACSWEEN, R.N.M. Isolation and characterization of a high molecular weight lymphocyte Fc receptor-blocking factor associated with renal allograft survival, 140
SASAKI, T. *see* TAKAHASHI, T.
SAVIGE, J.A., GALLICCHIO, M., GEORGIOU, T. & DAVIES, D.J. Diverse target antigens recognized by circulating antibodies in anti-neutrophil cytoplasm antibody-associated renal vasculitides, 238
SAYAMA, K., SHIRAISHI, S., SHIRAKATA, Y., KOBAYASHI, Y., OKADA, N., OKADA, H. & MIKI, Y. Characterization of homologous restriction factor (HRF20) in human skin and leucocytes, 355
SCHYBERG, T. *see* ROSS, C.
SCOTT, J.R. *see* PARK, M.I.
SEGAL, R. *see* MENDELOVIC, S.
SEKIYA, C. *see* KOHDA, H.
SHELLITO, J. *see* BECK, J.M.
SHERON, N., LAU, J.N., HOFFMAN, J., WILLIAMS, R. & ALEXANDER, G.J.M. Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humans, 427
SHIBATA, T. *see* TAGUCHI, H.
SHIMOMURA, C. *see* MIGITA, K.
SHIRAISHI, S. *see* SAYAMA, K.
SHOENFELD, Y. *see* MENDELOVIC, S.
SKERRITT, J.H. *see* DEVERY, J.M.
SMEENK, R.J.T. *see* TERMAAT, R.M.
SMITH-RAVIN, J., SPENCER, J., BEVERLEY, P.C.L. & ISAACSON, P.G. Characterization of two monoclonal antibodies (UCL4D12 and UCL3D3) that discriminate between human mantle zone and marginal zone B cells, 181
SNOW, K. *see* MATSUBAYASHI, S.
SOLDEVILLA, L. *see* TEN, R.M.
SPENCER, J. *see* SMITH-RAVIN, J.
SPYCHER, M.O. *see* JUNGI, T.W.
STEANSSON, K. *see* AARLI, J.A.
STEFURA, W. *see* HAYGLASS, K.T.
STELLA, M. *see* CASTAGNOLI, C.
STEWARD, M.W. *see* HOLLAND, G.P.
STRANNEGARD, O. *see* CONVERSE, P.J.
STURGESS, R.P., MACARTNEY, J.C., MAKGOBA, M.W., HUNG, C.-H., HASKARD, D.O. & CICLITIRA, P.J. Differential upregulation of intercellular adhesion molecule-1 in coeliac disease, 489
SUGIOKA, Y. *see* ARITA, C.
SUGIYAMA, T. *see* TAKAHASHI, T.
SUKARA, V.V. *see* BECK, J.M.
SVARVARE, M. *see* NILSSON, B.
SWAAK, A.J.G. *see* TERMAAT, R.M.

TADA, Y. *see* TSUKAMOTO, H.
TAGUCHI, H., KANOH, M., TAKUBO, N., KADOTA, S., KANAZAWA, K., SHIBATA, T. & UTSUMI, S. *In vitro* IgG rheumatoid factor production by CD5-negative murine B cells in response to immune complexes of lipopolysaccharide, 128
TAKAHASHI, T., IMAI, K., SUGIYAMA, T., SASAKI, T. & YACHI, A. Preparation of anti-T idiotype monoclonal antibody reacting with human T leukaemic cell lines and with a small percentage of peripheral T lymphocytes, 590
TAKAI, K., JOJIMA, K., SAKATOKU, J. & FUKUMOTO, T. Effects of FK506 on rat-thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry, 445
TAKEUCHI, M. *see* EMURA, M.
TAKUBO, N. *see* TAGUCHI, H.
TALAL, N. *see* MILLER, A.L.
TARKOWSKI, A. *see* TROLLMO, C.
TEICH ALASIA, S. *see* CASTAGNOLI, C.
TEJA-ISAVADHARAM, P. *see* BROWN, A.E.
TEN, R.M., KEPHART, G.M., POSADA, M., ABAITUA, I., SOLDEVILLA, L., KILBOURNE, E.M., DUNNETTE, S.L. & GLEICH, G.J. Participation of eosinophils in the toxic oil syndrome, 313
TER BORG, B.J., HORST, G., LIMBURG, P.C. & KALLENBERG, C.G.M. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus, 21
TERMAAT, R.M., BRINKMAN, K., NOSSENT, J.C., SWAAK, A.J.G., SMEENK, R.J.T. & BERDEN, J.H.M. Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations, 268
THOMSON, A.W. *see* WOO, J.
TONNEL, A.B. *see* LASSALLE, P.
TORRES, A. *see* IZQUIERDO, M.
TOUBERT, A., HAMACHI, M., RAFFOUX, C., PARK, M.S. & YU, D.T.Y. Epitope mapping of an HLA-B27 monoclonal antibody that also reacts with a 35-kD bacterial outer-membrane protein, 16
TOVO, P.A. *see* PASTORELLI, G.
TOWNES, A.S. *see* CREMER, M.A.
TREIBEL, F. *see* FARACE, F.
TROLLMO, C., CARLSTEIN, H. & TARKOWSKI, A. Intra-articular immunization induces strong systemic murine response in humans, 384
TSUCHIYA, N., HUSBY, G. & WILLIAMS, R.C. Antibodies to the peptide from the plasmid-coded *Yersinia* outer membrane protein (YOP1) in patients with ankylosing spondylitis, 493
TSUKADA, Y. *see* OKUBO, Y.
TSUKAMOTO, H., UEDA, A., NAGASAWA, K., TADA, Y. & NIHO, Y. Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus, 257
TURSZ, T. *see* FARACE, F.
TZIOUFAS, A.G. *see* KATZIKIS, P.D.

UEDA, A. *see* TSUKAMOTO, H.
UEDE, T. *see* KOHDA, H.
UEKI, Y. *see* MIGITA, K.
UTSUMI, S. *see* TAGUCHI, H.

VAN DER STELT, M.E. *see* POS, O.
VAN DER TEMPEL, G.L. *see* POS, O.
VAN DIJK, W. *see* POS, O.
VAN LAAR, J.M. *see* MILTENBURG, A.M.M.
VAN THIEL, D.H. *see* YOO, Y.K.
VAN VOOREN, J.-P. *see* HUYGEN, K.
VANDENBRUAENE, M. *see* VANHAM, G.
VANHAM, G., KESTENS, L., GIGASE, P., COLEBUNDERS, R. VANDENBRUAENE, M., BRIJS, L. & CEUPPENS, J.L. Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections, 3
VAUGHAN, J.H. *see* KOURI, T.
VICARI, A. *see* ZOCCHI, M.R.
VILLA, A. *see* ZOCCHI, M.R.
VOLLAR, L.M. *see* BRIEVA, J.A.
VOLPÉ, R. *see* MATSUBAYASHI, S.
VON ESSEN, R. *see* KOURI, T.
VOORBY, H.A.M., JEUCKEN, P.H.M. & DREXHAGE, H.A. A delayed-type hypersensitivity skin-test system using the insulinoma cell line RINm5F to monitor beta cell-specific cellular autoimmune reactivity in the spontaneously diabetic BB/O rat, 542
VUITTON, D.A. *see* BRESSON-HADNI, S.
VUITTON, D.A. *see* LIANCE, M.

WAGNER, F., ASSEMI, C., LERSCH, C., HART, R. & CLASSEN, M. Soluble interleukin-2 receptor and soluble CD8 in liver cirrhosis and obstructive jaundice, 344
WALKER, J. *see* FORTUNE, F.
WANG, S.R. *see* CHUANG, J.C.
WARE BRANCH, D. *see* PARK, M.I.
WATSON, C.M. *see* OWEN, S.J.
WAWRZYNCZAK, E.J. & DAVIES, A.J.S. Editorial Review: Strategies of antibody therapy of cancer, 189
WEBSTER, H.K. *see* BROWN, A.E.
WEETMAN, A.P., FREEMAN, M. & MORGAN, B.P. Thyroid follicular cell function after non-lethal complement membrane attack, 69
WHITESIDE, T.L. *see* YOO, Y.K.
WILLIAMS, R. *see* DE LA MATA, M.
WILLIAMS, R.C. *see* TSUCHIYA, N.
WILLIMS, R. *see* SHERON, N.
WING, M.G. *see* MONTGOMERY, A.M.P.

WING, M.G., MONTGOMERY, A.M.P., HARLEY, C. & LACHMANN, P.J. Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically, 208
WOLBINK, G.-J. *see* POS, O.
WOLLMANN, R.L. *see* AARLI, J.A.
WOO, J., PROPPER, D.J., MACLOED, A.M. & THOMSON, A.W. Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion, 462
WU, D.P., GILKESON, G.S., ARMITAGE, J., REICH, C.F. & PISETSKY, D.S. Selective recognition of DNA antigenic determinants by murine monoclonal anti-DNA antibodies, 33
WYNN, T.A. *see* HAAK-FRENDSCHO, M.

XAVIER, C. *see* CHIRON, M.

YACHI, A. *see* TAKAHASHI, T.
YAMANOUCHI, K. *see* IMAOKA, K.
YANO, S. *see* OKUBO, Y.
YOO, Y.K., GAVALER, J.B., CHEN, K., WHITESIDE, T.L. & VAN THIEL, D.H. The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals, 338
YOSHIDA, Y. *see* KOHDA, H.
YOSHIKAWA, Y. *see* IMAOKA, K.
YOUINOU, P.Y. *see* KATZIKIS, P.D.
YU, C.L. *see* CHUANG, J.C.
YU, D.T.Y. *see* TOUBERT, A.

ZOCCHI, M.R., POGGI, A., HELTAI, S., VILLA, A., INVERARDI, L., VICARI, A. & SABBADINI, M.G. Signal requirements for activation of leukaemic T cells from a chronic lymphocytic leukaemia (T-CLL), 108
ZWILLING, B.S., DARROW, R., MCPEEK, M., LAUFMAN, H. & PEARL, D. HLA class II glycoprotein expression by monocytes from HIV-infected individuals: differences in response to interferon-gamma, 553

Subject Index

1F5, 355
α1-acid glycoprotein, 579
α1-protease inhibitor, 579
Activation antigens, 102
Activation, 108
Adjuvant action, 221
Adjuvant arthritis, 307
Agar, 396
Allergen immunotherapy, 429
Alloantibodies, 462
Allospecific helper T cells, 527
Alveolar echinococcosis, 373, 378
Amino acids, 469
Anaphylatoxins, 359
Animal models, 542
Ankylosing spondylitis, 493
Anti-DNA antibodies, 33
Anti-heparan sulphate antibodies, 294
Anti-DNA, 268
Anti-HLA DR immunotoxin, 214
Anti-M7, 289
Anti-Sm antibodies, 27
Anti-T idiotype antibody, 590
Anti-cytoskeleton protein antibodies, 52
Anti-dsDNA antibodies, 522
Anti-glomerular antibodies, 238
Anti-mitochondrial antibodies, 289
Anti-neutrophil cytoplasmic antibodies, 233, 238, 244
Anti-nuclear antibodies, 238
Anti-nucleohistone antibodies, 522
Anti-schistosomiasis antibodies, 574
Anti-smooth muscle antibodies, 52
Antibodies, 440, 559
Antibody affinity, 221
Antibody repertoire, 369
Antibody therapy, 189
Antigens, 489
Autoaggressive cells, 86
Autoantibodies, 38, 227, 284
Autoantibody production, 533
Autoantigens, 284
Autoimmune hepatitis, 473
Autoimmunity, 57, 307, 527
Autologous mixed lymphocyte reaction, 174

B cell abnormality, 533
B cell differentiating factor, 133
B cell growth factor, 133
B cells, 181, 384, 411
B lymphocytes, 133
BCG, 567
BCG filtrate, 369
Bacteroides gingivalis (*Porphyromonas gingivalis*), 318
Behçet's syndrome, 326
Blocking activity, 363
Blocking factors, 140
Blood transfusion, 462
Bone marrow transplantation, 145

C3, 257
C5 convertase, 262
CD3–T cell receptor, 396
CD57$^+$ cells, 145
CD59, 355
CD8 lymphocytes, 396
CNPase, 86
CR1(CD35), 262
Cancer immunotherapy, 194
Cancer therapy, 189
Cartilage, 307
Cell phenotype, 378
Cellular immunity, 333, 373, 378
Chagas' disease, 93
Cholestasis, 344
Chronic active hepatitis B, 338
Chronic hepatitis B, 427
Coeliac disease, 333, 489
Collagen arthritis, 456
Collagen, 307
Complement, 69, 300, 359
Complement activation, 359
Complement production, 257
Cord blood mononuclear cells, 114
Cross-reactivity, 268, 294
Cyclosporin A, 462
Cytokines, 57
Cytomegalovirus, 559
Cytotoxic activity, 214
Cytotoxic T cells, 3
Cytotoxic T lymphocytes, 473
Cytotoxicity, 157, 499

DNA antigenicity, 33
DNA synthesis, 485
Degrading enzymes, 469
Delayed-type hypersensitivity, 373, 542
Dendritic cells, 275
Dexamethasone, 157
Dilated cardiomyopathy, 289

ELISA, 522
Echinococcus multilocularis, 373, 378
Elastase, 238
Endothelial cells, 38, 227
Enterobacteria, 16
Environmental agents, 515
Eosinophil granule, 313
Eosinophilia, 38
Eosinophils, 313
Established lesion, 456
Exacerbations, 21
Experimental glomerulonephritis, 450
Extracorporeal, 440

FK506, 445, 450, 456, 462
Factor I, 262
FCγ receptors, 140, 163
Fibroblasts, 350
Fimbriae, 318
Flow cytofluorometry, 445
Flow cytometry, 473
Fulminant hepatic failure, 479

Gammapathy, 294
Glycosylation, 579
Graft-*versus*-host disease, 527
Granuloma, 378
Graves' disease, 63, 69

HIV, 2, 10, 553, 559
HLA class I antigen secretion, 390
HLA class II, 326, 350, 553

HLA, 548
HLA-B27, 1, 16, 493
HLA-DR antigen expression, 338
HLA-DR antigens, 214
HLA-DR, 538
HRF20, 355
Hashimoto's thyroiditis, 63, 69
Heliobacter pylori, 485
H. pylori antibody, 485
Heparan sulphate, 268
Hepatitis B, chronic, 427
Hexose monophosphate shunt, 170
Heymann's nephritis, 450
Human lymphocyte activation, 390
Human monoclonal antibodies, 44
Human ovarian follicular fluid, 359
Human skin, 355
Hydatid disease, 373, 378
Hypertrophic scars, 350

ICAM-1, 489
Idiopathic pulmonary fibrosis, 133
Idiotypes, 27, 318, 509
Idiotypic network, 504
IgA, 326
IgA subclasses, 318
IgE regulation, 429
IgE responses, 423
IgE synthesis, 114, 120
IgG, 262
IgG rheumatoid factor, 128
IgG subclasses, 574
IgG4, 574
Immune complex disease, 515
Immune complexes, 300
Immune defects, 344
Immune interferon, 214
Immunoadsorption, 440
Immunoblot, 559
Immunoconglutinins, 262
Immunodeficiency patients, 120
Immunoglobulin subclasses, 411
Immunohistochemistry, 445
Immunoradiometric assay, 574
Immunosuppression, 174, 456
Immunosuppressive agent, 450
Immunotherapy, 200, 567
Infections, 515
Inflammation, 579
Inflammatory arthritis, 1
Influenza virus, 384, 435
Insulin-dependent diabetes, 44, 538
Interferon, 57
Interferon-alpha, 338
Interferon-gamma, 63, 81, 97, 194, 208, 221, 390, 429, 485, 548, 583
Interleukin-1, 157, 548
Interleukin-2 receptors, 21, 75
Interleukin-2, 63, 151, 194, 583
Interleukin-4, 114, 120, 583
Interleukin-6, 384, 427, 533, 579
Intestinal mucosa, 411
Intra-articular immunization, 384
Intra-epithelial lymphocytes, 81
Intranasal administration, 435
Intrapleural, 151
Intravenous IgG, 163
Iscom, 435
Islet cells, 44

J chain, 411

Keratinocytes, 350

Leprosy, 567
Leucocytes, 355
Leukaemia, 108
Lipopolysaccharide, 128, 318, 515
Liver cirrhosis, 338, 344
Liver lymphocytes, 338
Lupus nephritis, 300
Ly-1 B cells, 128
Lymphocyte proliferation, 469
Lymphocyte subsets, 338, 473
Lymphocytes, 108, 170, 462, 489
Lymphoid tissues, 411
Lymphokine-activated killer cells, 81, 151, 416, 583

MHC class i antigens, 102
Macrophage activation, 97
Macrophage procoagulant activity, 333
Macrophages, 10, 157, 404
Major basic protein, 313
Malaria, 97
Mantle zones, 181
Marginal zones, 181
Membrane attack complex, 69
Membrane cytoplasm, 44
Microscopic polyarteritis, 233
Modified allergens, 429
Molecular mimicry, 16
Monitoring, 244
Monoclonal antibodies, 33, 93, 181, 445, 590
Monoclonal antibodies, human, 44
Monoclonal antibody heteroconjugate, 200
Monoclonal cryoglobulins, 509
Monoclonal immunoglobulins, 294
Monoclonal plasma cells, 509
Monocytes, 10, 163, 257, 552
Mononuclear cells, 473
Mononuclear phagocyte system, 300
Multiple sclerosis, 86
Murine models of autoimmunity, 33
Muscle proteins, 284
Myasthenia gravis, 284
Mycobacterium leprae, 567
Myelin degradation assay, 86
Myeloperoxidase, 238
Myocarditis, 289
$NADP^+$, 170
NADPH, 170
NZB/W F1 mice, 533
Natural killer cells, 3, 151
Neopterin, 97
Nephritis modulation, 515
Neutrophil cytoplasm, 227

Opportunistic infections, 3
Overshoot, 440
Ovulation, 359
Oxidative burst, 10

PPD, 200
Pathogenesis, 227
Peptides, 275
Periodontal diseases, 318
Phagocytosis, 163
Plasmodium falciparum, 97
Platelet allotransfusion, 102
Polyclonal B cell activation, 300
Polymorphism, 538
Proliferation, 275
Pyruvate, 170

Quil A, 435

RINm5F, 542
Rabbit, 522
Rats, 440

Rebound, 440
Recurrent abortion, 363
Regulation of HLA class I, 390
Renal allografts, 140
Rheumatoid arthritis, 250, 499
Rheumatoid factors, 250, 509
Rinderpest virus, 522

SLE relatives, 504
Sarcosine dehydrogenase, 289
Schistosomiasis, 574
Sensibilization, 542
Serological tests, 93
Serology, 567
Sjögren's syndrome, 509
Skin tests, 542
Skin, human, 355
Solid-phase radioimmunoassay, 233
Soluble CD8, 344
Soluble HLA class I antigens, 390
Soluble interleukin-2 receptor, 344
Subcutaneous administration, 435
Synovial fluid, 499
Systemic lupus erythematosus nephritis, 268
Systemic lupus erythematosus, 21, 33, 257, 504, 515
Systemic vasculitis, 227

T cell activation, 21
T cell clones, 499
T cell dysfunction, 145
T cell epitope, 275
T cell receptor, 538, 590
T cell responses, 504
T cell subsets, 27
T cells, 384, 416, 559
T gamma cells, 174
T helper clones, 200
T lymphocytes, 133
Takayasu's arteritis, 233
Therapeutic effect, 456
Thymoma, 284
Thymus, 445
Thyroglobulin, 275
Thyrocytes, 548
Thyroid follicular cells, 69
Thyroid peroxidase, 275
Toxic oil syndrome, 313
Transforming growth factor-β1, 404, 583
Trypanosoma cruzi antigen, 93
Tumour cytostasis, 200, 208
Tumour necrosis factor, 208, 427, 479, 548
Tumour necrosis factor-alpha, 583

Wegener's granulomatosis, 233, 244
Wild mice, 369

Yersinia antigen, 493